MPWT
KROS icon

MassMutual Private Wealth & Trust’s Keros Therapeutics KROS Stock Holding History

MassMutual Private Wealth & Trust’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-78
Closed -$1.24K – 2429
2024
Q4 		$1.24K Buy
+78
New +$4.05K ﹤0.01% 1972

Other funds holding KROS

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MassMutual Private Wealth & Trust's KROS Position: Q1 2025 in Review

MassMutual Private Wealth & Trust sold out of Keros Therapeutics (KROS) in Q1 2025, closing a stake of 78 shares — an estimated $1.24K sold.

MassMutual Private Wealth & Trust first reported a position in KROS in Q4 2024 and held it in 1 quarter. The position peaked at $1.24K in Q4 2024. 156 funds tracked by Wall St. Rank hold KROS as of Q1 2025.

  • MassMutual Private Wealth & Trust reported no remaining Keros Therapeutics position as of Q1 2025 after selling out during the quarter.
  • MassMutual Private Wealth & Trust sold 78 Keros Therapeutics shares in Q1 2025, an estimated $1.24K.
  • MassMutual Private Wealth & Trust first reported a position in Keros Therapeutics in Q4 2024 and held it in 1 quarter.
  • MassMutual Private Wealth & Trust's Keros Therapeutics position peaked at $1.24K in Q4 2024.
  • 156 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2025.

Based on MassMutual Private Wealth & Trust's 13F filing for Q1 2025, filed 1 Apr 2025.